Litcius/Paper detail

Isavuconazole for treatment of refractory coccidioidal meningitis with concomitant cerebrospinal fluid and plasma therapeutic drug monitoring

Matthew R Davis, Sandy Y. Chang, Pryce Gaynor, Erin K McCreary, Paul R Allyn

2021Medical Mycology15 citationsDOIOpen Access PDF

Abstract

Coccidioidal meningitis (CM) is a life-threatening infection with limited treatment options. Small series have reported success with isavuconazole; however, limited data exist on cerebrospinal fluid (CSF) penetration. Paired plasma and CSF isavuconazole concentrations were measured. Eleven CSF levels were tested, (7 ventricular, 4 lumbar) in three CM patients. Ventricular CSF levels were undetectable despite detectable plasma levels. All lumbar CSF levels were detectable (mean 1.00 µg/ml). Three pairs of lumbar CSF/plasma concentrations taken within 1 h of each other yielded a mean CSF/plasma ratio of 0.31. Isavuconazole was detectable in lumbar but not ventricular CSF in three patients treated for refractory CM. LAY SUMMARY: Isavuconazole is a triazole antifungal that has been used as salvage therapy in the treatment of coccidioidal meningitis (CM). Few data exist characterizing its concentration in the cerebrospinal fluid (CSF). We report tandem plasma and CSF concentrations of isavuconazole in three patients with CM.

Topics & Concepts

Cerebrospinal fluidRefractory (planetary science)MedicineLumbarCSF albuminLumbar punctureConcomitantMeningitisInternal medicineGastroenterologySurgeryBiologyAstrobiologyFungal Infections and StudiesAntifungal resistance and susceptibilityInfectious Diseases and Tuberculosis
Isavuconazole for treatment of refractory coccidioidal meningitis with concomitant cerebrospinal fluid and plasma therapeutic drug monitoring | Litcius